Biocon Limited
BIOCON
주식 순위
#3395
Biocon Limited functions as a biopharmaceutical firm, engaged in the production... Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.
주가
$3.75
마지막 동기화: 2026-10-19
시가총액
$5.13B
변동 (1일)
-2.30%
변동 (1년)
-9.79%
국가
IN
거래 Biocon Limited (BIOCON)
카테고리
Healthcare
Biocon Limited (BIOCON)의 매출
Jun 2026 기준 매출 TTM: $1.91B
Biocon Limited의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.91B입니다. 2024년에 회사는 $1.77B의 수익을 올렸으며 이는 2023년의 $1.36B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Biocon Limited의 수익 기록 (2004 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.91B | 6.92% |
| 2025 | $1.78B | 0.84% |
| 2024 | $1.77B | 30.15% |
| 2023 | $1.36B | 26.12% |
| 2022 | $1.08B | 10.49% |
| 2021 | $975.78M | 16.67% |
| 2020 | $836.33M | 5.32% |
| 2019 | $794.12M | 25.39% |
| 2018 | $633.30M | 5.55% |
| 2017 | $600.02M | 18.75% |
| 2016 | $505.27M | 2.04% |
| 2015 | $495.17M | -3.94% |
| 2014 | $515.48M | 12.70% |
| 2013 | $457.40M | 13.20% |
| 2012 | $404.08M | -21.72% |
| 2011 | $516.22M | 13.85% |
| 2010 | $453.41M | 67.79% |
| 2009 | $270.22M | 29.75% |
| 2008 | $208.27M | 9.73% |
| 2007 | $189.80M | 22.96% |
| 2006 | $154.36M | 4.28% |
| 2005 | $148.03M | 28.03% |
| 2004 | $115.62M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 561.69% |
US
|
|
| $2.23B | 16.78% |
US
|
|
| $15.74B | 725.22% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 215.60% |
NL
|
